The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53

Cancer Letters

Volumn 271, Issue 1, 2008, Pages 64-80

  Tam, Chun Wai ^a   Liu, Vincent Wing Sun ^a   Leung, Wai Ying ^a   Yao, Kwok Ming ^a   Shiu, Stephen Yuen Wing ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Breast; Liver; p53; Prostate; sPDZD2

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROGEN PEROXIDE; MUTANT PROTEIN; PDZ PROTEIN; PROTEIN P21; PROTEIN P53; SECRETED PDZ DOMAIN CONTAINING PROTEIN 2; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER CELL CULTURE; CELL AGING; CELL STRAIN MCF 7; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; LIVER CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WILD TYPE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 53049106876     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.05.047     Document Type: Article

References (67)

1. Chang C., Simmons D.T., Martin M.A., and Mora P.T. Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J. Virol. 31 (1979) 463-471
2. DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., and Old L.J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76 (1979) 2420-2424
3. Kress M., May E., Cassingena R., and May P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J. Virol. 31 (1979) 472-483
4. Lane D.P., and Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278 (1979) 261-263
5. Linzer D.I., and Levine A.J. Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17 (1979) 43-52
6. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283
7. El-Deiry W.S. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22 (2003) 7486-7495
8. Fridman J.S., and Lowe S.W. Control of apoptosis by p53. Oncogene 22 (2003) 9030-9040
9. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54 (1994) 4855-4878
10. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
11. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
12. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 26 (2007) 2145-2156
13. Vousden K.H., and Prives C. p53 and prognosis: new insights and further complexity. Cell 120 (2005) 7-10
14. Soussi T., and Lozano G. p53 mutation heterogeneity in cancer. Biochem. Biophys. Res. Commun. 331 (2005) 834-842
15. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006) 1323-1334
16. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
17. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
18. Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., Tanaka A., Kotani H., Nomura N., and Ohara O. Prediction of the coding sequences of unidentified human genes. VII, The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res. 4 (1997) 141-150
19. Thomas M.K., Yao K.M., Tenser M.S., Wong G.G., and Habener J.F. Bridge-1, a novel PDZ-domain coactivator of E2A-mediated regulation of insulin gene transcription. Mol. Cell. Biol. 19 (1999) 8492-8504
20. Deguchi M., Iizuka T., Hata Y., Nishimura W., Hirao K., Yao I., Kawabe H., and Takai Y. PAPIN. A novel multiple PSD-95/Dlg-A/ZO-1 protein interacting with neural plakophilin-related armadillo repeat protein/delta-catenin and p0071. J. Biol. Chem. 275 (2000) 29875-29880 Erratum, J. Biol. Chem. 277, 35778
21. Chaib H., Rubin M.A., Mucci N.R., Li L., Taylor J.M.G., Day M.L., Rhim J.S., and Macoska J.A. Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors. Cancer Res. 61 (2001) 2390-2394
22. Tam C.W., Cheng A.S., Ma R.Y., Yao K.M., and Shiu S.Y.W. Inhibition of prostate cancer cell growth by human secreted PDZ domain-containing protein 2, a potential autocrine prostate tumor suppressor. Endocrinology 147 (2006) 5023-5033
23. Yeung M.L., Tam T.S., Tsang A.C., and Yao K.M. Proteolytic cleavage of PDZD2 generates a secreted peptide containing two PDZ domains. EMBO Rep. 4 (2003) 412-418
24. Lain S., and Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur. J. Cancer 39 (2003) 1053-1060
25. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
26. Ma R.Y., Tam T.S., Suen A.P., Yeung P.M., Tsang S.W., Chung S.K., Thomas M.K., Leung P.S., and Yao K.M. Secreted PDZD2 exerts concentration-dependent effects on the proliferation of INS-1E cells. Int. J. Biochem. Cell Biol. 38 (2006) 1015-1022
27. Raman V., Martensen S.A., Reisman D., Evron E., Odenwald W.F., Jaffee E., Marks J., and Sukumar S. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405 (2000) 974-978
28. Wei X., Xu H., and Kufe D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 67 (2007) 1853-1858
29. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., MacDougald O.A., Cho K.R., and Fearon E.R. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17 (2007) 1298-1307
30. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., Peacocke M., and Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92 (1995) 9363-9367
31. Carroll A.G., Voeller H.J., Sugars L., and Gelmann E.P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23 (1993) 123-134
32. van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., and Lucia M.S. Molecular characterization of human prostate carcinoma cell lines. Prostate 57 (2003) 205-225
33. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace Jr. A.J., and Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57 (1997) 4285-4300
34. Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J., and Ozturk M. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J. 7 (1993) 1407-1413
35. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Signer S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weslon A., Modali R., Harris C.C., and Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature 342 (1989) 705-708
36. He L., He X., Lowe S.W., and Hannon G.J. MicroRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 7 (2007) 819-822
37. Termini J. Hydroperoxide-induced DNA damage and mutations. Mutat Res. 450 (2000) 107-124
38. Balint E.E., and Vousden K.H. Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer 85 (2001) 1813-1823
39. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
40. Bond G.L., Hu W., and Levine A.J. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5 (2005) 3-8
41. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95 (1998) 5-8
42. Toledo F., and Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6 (2006) 909-923
43. Tuck S.P., and Crawford L. Characterization of the human p53 gene promoter. Mol. Cell. Biol. 9 (1989) 2163-2172
44. Sun X., Shimizu H., and Yamamoto K. Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol. Cell. Biol. 15 (1995) 4489-4496
45. Noda A., Toma-Aiba Y., and Fujiwara Y. A unique, short sequence determines p53 gene basal and UV-inducible expression in normal human cells. Oncogene 19 (2000) 21-31
46. Ahmed M.M. Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors. Curr. Cancer Drug Targets 4 (2004) 43-52
47. Furlong E.E., Rein T., and Martin F. YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity. Mol. Cell. Biol. 16 (1996) 5933-5945
48. Johansson E.M., Kannius-Janson M., Gritli-Linde A., Bjursell G., and Nilsson J. Nuclear factor 1-C2 is regulated by prolactin and shows a distinct expression pattern in the mouse mammary epithelial cells during development. Mol. Endocrinol. 19 (2005) 992-1003
49. Kirch H.C., Flaswinkel S., Rumpf H., Brockmann D., and Esche H. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene 18 (1999) 2728-2738
50. Nair P., Muthukkumar S., Sells S.F., Han S.S., Sukhatme V.P., and Rangnekar V.M. Early growth response-1-dependent apoptosis is mediated by p53. J. Biol. Chem. 272 (1997) 20131-20138
51. Qin C., Nguyen T., Stewart J., Samudio I., Burghardt R., and Safe S. Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor kappaB/CCAAT-binding transcription factor-1 complex. Mol. Endocrinol. 16 (2002) 1793-1809
52. Wang S., and El-Deiry W.S. p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res. 66 (2006) 6982-6989
53. Kawauchi J., Zhang C., Nobori K., Hashimoto Y., Adachi M.T., Noda A., Sunamori M., and Kitajima S. Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription. J. Biol. Chem. 277 (2002) 39025-39034
54. Li C., Ahlborn T.E., Tokita K., Boxer L.M., Noda A., and Liu J. The critical role of the PE21 element in oncostatin M-mediated transcriptional repression of the p53 tumor suppressor gene in breast cancer cells. Oncogene 20 (2001) 8193-8202
55. Rowland B.D., Bernards R., and Peeper D.S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 7 (2005) 1074-1082
56. Stuart E.T., Haffner R., Oren M., and Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 14 (1995) 5638-5645
57. Yan J., Jiang J., Lim C.A., Wu Q., Ng H.H., and Chin K.C. BLIMP1 regulates cell growth through repression of p53 transcription. Proc. Natl. Acad. Sci. USA 104 (2007) 1841-1846
58. Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., and Dynlacht B.D. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 16 (2002) 245-256
59. Sui G., Affar el B., Shi Y., Brignone C., Wall N.R., Yin P., Donohoe M., Luke M.P., Calvo D., Grossman S.R., and Shi Y. Yin Yang 1 is a negative regulator of p53. Cell 117 (2004) 859-872
60. Gurova K.V., Hill J.E., Guo C., Prokvolit A., Burdelya L.G., Samoylova E., Khodyakova A.V., Ganapathi R., Ganapathi M., Tararova N.D., Bosykh D., Lvovskiy D., Webb T.R., Stark G.R., and Gudkov A.V. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc. Natl. Acad. Sci. USA 102 (2005) 17448-17453
61. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7 (2001) 683-694
62. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 (2005) 2899-2908
63. Thompson T., Tovar C., Yang H., Carvajal D., Vu B.T., Xu Q., Wahl G.M., Heimbrook D.C., and Vassilev L.T. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279 (2004) 53015-58022
64. Klein C., and Vassilev L.T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 91 (2004) 1415-1419
65. Vassilev L.T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3 (2004) 419-421
66. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., and Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA 100 (2003) 8424-8429
67. Gurova K.V., Rokhlin O.W., Budanov A.V., Burdelya L.G., Chumakov P.M., Cohen M.B., and Gudkov A.V. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res. 63 (2003) 2905-2912